Krzych Łukasz J, Wybraniec Maciej T
Department of Cardiac Anaesthesia and Intensive Therapy, Silesian Centre for Heart Diseases, 9 Curie-Sklodowskiej St., 41-800 Zabrze, Poland.
Curr Vasc Pharmacol. 2015;13(5):578-86. doi: 10.2174/1570161112666140224145707.
Glycaemic management is of paramount importance in the cardiac surgery setting. A growing body of evidence confirms a J-shaped relationship between blood glucose (BG) level and perioperative morbidity and mortality. On one hand, acute hypoglycaemia causes irreversible cerebral damage. On the other hand, hyperglycaemia increases the risk of infections, acute kidney injury, atrial fibrillation, low cardiac output syndrome, cerebrovascular accidents and cognitive impairment. Also, high BG variability, even within the therapeutic window, may deteriorate the outcome. Therefore, moderate perioperative insulin management is usually recommended, with target BG adjusted to individual needs and possibilities. Continuous BG monitoring is a promising tool that should help practitioners in everyday decision-making process of glycaemic control. This review summarises the current evidence-based knowledge on the perioperative management of hyperglycaemia.
血糖管理在心脏手术中至关重要。越来越多的证据证实,血糖(BG)水平与围手术期发病率和死亡率之间呈J形关系。一方面,急性低血糖会导致不可逆的脑损伤。另一方面,高血糖会增加感染、急性肾损伤、心房颤动、低心排血量综合征、脑血管意外和认知障碍的风险。此外,即使在治疗窗口内,高血糖变异性也可能使预后恶化。因此,通常建议进行适度的围手术期胰岛素管理,将目标血糖根据个体需求和可能性进行调整。持续血糖监测是一种很有前景的工具,应有助于从业者在血糖控制的日常决策过程中做出决策。本综述总结了目前关于围手术期高血糖管理的循证知识。